Abstract:Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% of patients gain benefit. A key to understanding what differentiates treatment response from non-response is better defining the role of the innate immune system in anti-tumor immunity and immune tolerance. Teleologically, myeloid cells, including macrophages, dendritic cells, monocytes, and neutrophils, initiate a response to invading pathogens and tissue repair after pathogen clearance is successfully accomplished. However, in the tumor microenvironment (TME), these innate cells are hijacked by the tumor cells and are imprinted to furthering tumor propagation and dissemination. Major advancements have been made in the field, especially related to the heterogeneity of myeloid cells and their function in the TME at the single cell level, a topic that has been highlighted by several recent international meetings including the 2021 China Cancer Immunotherapy workshop in Beijing. Here, we provide an up-to-date summary of the mechanisms by which major myeloid cells in the TME facilitate immunosuppression, enable tumor growth, foster tumor plasticity, and confer therapeutic resistance. We discuss ongoing strategies targeting the myeloid compartment in the preclinical and clinical settings which include: (1) altering myeloid cell composition within the TME; (2) functional blockade of immune-suppressive myeloid cells; (3) reprogramming myeloid cells to acquire pro-inflammatory properties; (4) modulating myeloid cells via cytokines; (5) myeloid cell therapies; and (6) emerging targets such as Siglec-15, TREM2, MARCO, LILRB2, and CLEVER-1. There is a significant promise that myeloid cell-based immunotherapy will help advance immuno-oncology in years to come.

Targeting Innate Sensing in the Tumor Microenvironment to Improve Immunotherapy

Targeting Innate Immunity in Cancer Therapy

Exploiting innate immunity for cancer immunotherapy

Innate Immunity in Cancer Biology and Therapy

Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy

Harnessing innate immune pathways for therapeutic advancement in cancer

Targeting the Innate Immune System with Nanoparticles for Cancer Immunotherapy

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Innate Immune Cells in Tumour Microenvironment: A New Frontier in Cancer Immunotherapy

Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy

Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy

Emerging nanotechnological strategies to reshape tumor microenvironment for enhanced therapeutic outcomes of cancer immunotherapy.

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Cancer and Innate Immune System Interactions

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

Promising Targets For Cancer Immunotherapy: Tlrs, Rlrs, And Sting-Mediated Innate Immune Pathways

Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy

Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy

The Role of Traditional Chinese Medicine in Cancer Immunotherapy: Current Status and Future Directions.

The Role of Innate Immune Cells As Modulators of the Tumor Microenvironment in the Metastasis and Treatment of Pancreatic Cancer